6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      MCPIP1-mediated NFIC alternative splicing inhibits proliferation of triple-negative breast cancer via cyclin D1-Rb-E2F1 axis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Triple-negative breast cancer (TNBC) is the most aggressive subtype with the worst prognosis and the highest metastatic and recurrence potential, which represents 15–20% of all breast cancers in Chinese females, and the 5-year overall survival rate is about 80% in Chinese women. Recently, emerging evidence suggested that aberrant alternative splicing (AS) plays a crucial role in tumorigenesis and progression. AS is generally controlled by AS-associated RNA binding proteins (RBPs). Monocyte chemotactic protein induced protein 1 (MCPIP1), a zinc finger RBP, functions as a tumor suppressor in many cancers. Here, we showed that MCPIP1 was downregulated in 80 TNBC tissues and five TNBC cell lines compared to adjacent paracancerous tissues and one human immortalized breast epithelial cell line, while its high expression levels were associated with increased overall survival in TNBC patients. We demonstrated that MCPIP1 overexpression dramatically suppressed cell cycle progression and proliferation of TNBC cells in vitro and repressed tumor growth in vivo. Mechanistically, MCPIP1 was first demonstrated to act as a splicing factor to regulate AS in TNBC cells. Furthermore, we demonstrated that MCPIP1 modulated NFIC AS to promote CTF5 synthesis, which acted as a negative regulator in TNBC cells. Subsequently, we showed that CTF5 participated in MCPIP1-mediated antiproliferative effect by transcriptionally repressing cyclin D1 expression, as well as downregulating its downstream signaling targets p-Rb and E2F1. Conclusively, our findings provided novel insights into the anti-oncogenic mechanism of MCPIP1, suggesting that MCPIP1 could serve as an alternative treatment target in TNBC.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Hallmarks of Cancer: The Next Generation

            The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metabolism and evading immune destruction. In addition to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment." Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer. Copyright © 2011 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Integrative Genomics Viewer

              To the Editor Rapid improvements in sequencing and array-based platforms are resulting in a flood of diverse genome-wide data, including data from exome and whole genome sequencing, epigenetic surveys, expression profiling of coding and non-coding RNAs, SNP and copy number profiling, and functional assays. Analysis of these large, diverse datasets holds the promise of a more comprehensive understanding of the genome and its relation to human disease. Experienced and knowledgeable human review is an essential component of this process, complementing computational approaches. This calls for efficient and intuitive visualization tools able to scale to very large datasets and to flexibly integrate multiple data types, including clinical data. However, the sheer volume and scope of data poses a significant challenge to the development of such tools. To address this challenge we developed the Integrative Genomics Viewer (IGV), a lightweight visualization tool that enables intuitive real-time exploration of diverse, large-scale genomic datasets on standard desktop computers. It supports flexible integration of a wide range of genomic data types including aligned sequence reads, mutations, copy number, RNAi screens, gene expression, methylation, and genomic annotations (Figure S1). The IGV makes use of efficient, multi-resolution file formats to enable real-time exploration of arbitrarily large datasets over all resolution scales, while consuming minimal resources on the client computer (see Supplementary Text). Navigation through a dataset is similar to Google Maps, allowing the user to zoom and pan seamlessly across the genome at any level of detail from whole-genome to base pair (Figure S2). Datasets can be loaded from local or remote sources, including cloud-based resources, enabling investigators to view their own genomic datasets alongside publicly available data from, for example, The Cancer Genome Atlas (TCGA) 1 , 1000 Genomes (www.1000genomes.org/), and ENCODE 2 (www.genome.gov/10005107) projects. In addition, IGV allows collaborators to load and share data locally or remotely over the Web. IGV supports concurrent visualization of diverse data types across hundreds, and up to thousands of samples, and correlation of these integrated datasets with clinical and phenotypic variables. A researcher can define arbitrary sample annotations and associate them with data tracks using a simple tab-delimited file format (see Supplementary Text). These might include, for example, sample identifier (used to link different types of data for the same patient or tissue sample), phenotype, outcome, cluster membership, or any other clinical or experimental label. Annotations are displayed as a heatmap but more importantly are used for grouping, sorting, filtering, and overlaying diverse data types to yield a comprehensive picture of the integrated dataset. This is illustrated in Figure 1, a view of copy number, expression, mutation, and clinical data from 202 glioblastoma samples from the TCGA project in a 3 kb region around the EGFR locus 1, 3 . The investigator first grouped samples by tumor subtype, then by data type (copy number and expression), and finally sorted them by median copy number over the EGFR locus. A shared sample identifier links the copy number and expression tracks, maintaining their relative sort order within the subtypes. Mutation data is overlaid on corresponding copy number and expression tracks, based on shared participant identifier annotations. Several trends in the data stand out, such as a strong correlation between copy number and expression and an overrepresentation of EGFR amplified samples in the Classical subtype. IGV’s scalable architecture makes it well suited for genome-wide exploration of next-generation sequencing (NGS) datasets, including both basic aligned read data as well as derived results, such as read coverage. NGS datasets can approach terabytes in size, so careful management of data is necessary to conserve compute resources and to prevent information overload. IGV varies the displayed level of detail according to resolution scale. At very wide views, such as the whole genome, IGV represents NGS data by a simple coverage plot. Coverage data is often useful for assessing overall quality and diagnosing technical issues in sequencing runs (Figure S3), as well as analysis of ChIP-Seq 4 and RNA-Seq 5 experiments (Figures S4 and S5). As the user zooms below the ~50 kb range, individual aligned reads become visible (Figure 2) and putative SNPs are highlighted as allele counts in the coverage plot. Alignment details for each read are available in popup windows (Figures S6 and S7). Zooming further, individual base mismatches become visible, highlighted by color and intensity according to base call and quality. At this level, the investigator may sort reads by base, quality, strand, sample and other attributes to assess the evidence of a variant. This type of visual inspection can be an efficient and powerful tool for variant call validation, eliminating many false positives and aiding in confirmation of true findings (Figures S6 and S7). Many sequencing protocols produce reads from both ends (“paired ends”) of genomic fragments of known size distribution. IGV uses this information to color-code paired ends if their insert sizes are larger than expected, fall on different chromosomes, or have unexpected pair orientations. Such pairs, when consistent across multiple reads, can be indicative of a genomic rearrangement. When coloring aberrant paired ends, each chromosome is assigned a unique color, so that intra- (same color) and inter- (different color) chromosomal events are readily distinguished (Figures 2 and S8). We note that misalignments, particularly in repeat regions, can also yield unexpected insert sizes, and can be diagnosed with the IGV (Figure S9). There are a number of stand-alone, desktop genome browsers available today 6 including Artemis 7 , EagleView 8 , MapView 9 , Tablet 10 , Savant 11 , Apollo 12 , and the Integrated Genome Browser 13 . Many of them have features that overlap with IGV, particularly for NGS sequence alignment and genome annotation viewing. The Integrated Genome Browser also supports viewing array-based data. See Supplementary Table 1 and Supplementary Text for more detail. IGV focuses on the emerging integrative nature of genomic studies, placing equal emphasis on array-based platforms, such as expression and copy-number arrays, next-generation sequencing, as well as clinical and other sample metadata. Indeed, an important and unique feature of IGV is the ability to view all these different data types together and to use the sample metadata to dynamically group, sort, and filter datasets (Figure 1 above). Another important characteristic of IGV is fast data loading and real-time pan and zoom – at all scales of genome resolution and all dataset sizes, including datasets comprising hundreds of samples. Finally, we have placed great emphasis on the ease of installation and use of IGV, with the goal of making both the viewing and sharing of their data accessible to non-informatics end users. IGV is open source software and freely available at http://www.broadinstitute.org/igv/, including full documentation on use of the software. Supplementary Material 1
                Bookmark

                Author and article information

                Contributors
                yfzhouwhu@163.com
                Journal
                Cell Death Dis
                Cell Death Dis
                Cell Death & Disease
                Nature Publishing Group UK (London )
                2041-4889
                6 April 2021
                6 April 2021
                April 2021
                : 12
                : 4
                : 370
                Affiliations
                [1 ]GRID grid.413247.7, Hubei Key Laboratory of Tumor Biological Behaviors, , Zhongnan Hospital of Wuhan University, ; Wuhan, China
                [2 ]GRID grid.413247.7, Department of Radiation and Medical Oncology, , Zhongnan Hospital of Wuhan University, ; Wuhan, China
                [3 ]GRID grid.413247.7, Hubei Cancer Clinical Study Center, , Zhongnan Hospital of Wuhan University, ; Wuhan, China
                Author information
                http://orcid.org/0000-0002-6440-582X
                http://orcid.org/0000-0003-1894-0853
                Article
                3661
                10.1038/s41419-021-03661-4
                8024338
                33824311
                09ae46ee-6741-40af-995b-8e67108f8490
                © The Author(s) 2021

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 20 October 2020
                : 18 March 2021
                : 23 March 2021
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100010849, Health and Family Planning Commission of Wuhan Municipality;
                Award ID: No. WX17Q38
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100001809, National Natural Science Foundation of China (National Science Foundation of China);
                Award ID: 81472799
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2021

                Cell biology
                cancer,cancer genetics
                Cell biology
                cancer, cancer genetics

                Comments

                Comment on this article